Key result
SGLT2 inhibitors increase genital mycotic infections in older HF patients, but rarely require discontinuation.
Why the study?
SGLT2i improve outcomes across the HF spectrum, but genitourinary adverse events may complicate their use in older adults with frailty, multimorbidity, lower urinary tract dysfunction, and concomitant diuretic therapy.
In frail older adults with heart failure taking SGLT2 inhibitors, most uncomplicated genitourinary adverse events can be managed without permanent drug discontinuation using a frailty-informed approach.
Answers are grounded in this paper and cite their sources.
GU risks may influence SGLT2i use in frail older HF patients; leaves open targeted prevention trials.
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes across the heart failure (HF) spectrum, but genitourinary (GU) adverse events may complicate their use in older adults with frailty, multimorbidity, lower urinary tract dysfunction, and concomitant diuretic therapy. This review evaluates GU safety, prevention, and management during SGLT2i therapy in older adults with HF. A targeted narrative review of the literature was conducted using PubMed, supplemented by clinical guidelines, multidisciplinary consensus documents, and evidence syntheses, with the literature search updated through 20 September 2026. Priority was given to clinically relevant studies involving older adults with HF; evidence from broader populations was considered when direct evidence was unavailable. Genital mycotic infections are a consistent class-associated adverse event, whereas evidence regarding bacterial urinary tract infections (UTIs) remains mixed, and a consistent increase in severe UTI or urosepsis has not been established. In older adults with HF, frailty, urinary dysfunction, impaired mobility or cognition, and caregiver dependence may increase the clinical burden of GU symptoms and complicate their recognition and management. Osmotic diuresis, congestion, and concomitant loop-diuretic therapy may cause urinary symptoms that are mistaken for infection, contributing to unnecessary investigations or treatment. Evidence supporting non-antibiotic prophylaxis is predominantly indirect and does not justify routine preventive treatment. Most uncomplicated GU events can be managed without discontinuing SGLT2i therapy. A frailty-informed approach integrating symptom-driven assessment, antimicrobial stewardship, individualized volume management, and clinically appropriate temporary interruption and reinitiation may help preserve treatment persistence while maintaining patient safety. Further studies in frail older adults with HF are needed to define effective preventive and management strategies.
No takes yet. Share an insight, caveat, or question.
Cacciapuoti et al. (2026) conducted a review in Heart failure in older adults with frailty, multimorbidity, lower urinary tract dysfunction, and concomitant diuretic therapy. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) was evaluated on Genitourinary adverse events (genital mycotic infections, bacterial urinary tract infections, severe UTI, urosepsis) and treatment persistence. SGLT2 inhibitors consistently increase genital mycotic infections in older adults with heart failure, though most uncomplicated events can be managed without discontinuing therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: